Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study (Q34132839)

31 July 2017

Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study (English)

1 reference

31 July 2017

1 reference

Florence Laigle-Donadey

10

object named as

Florence Laigle-Donadey

0 references

Olivier Chinot

object named as

Olivier Chinot

15

1 reference

ORCID Public Data File 2021

Christophe Parizot

9

object named as

Christophe Parizot

1 reference

31 July 2017

11

Guy Gorochov

1 reference

31 July 2017

13

Marc Sanson

1 reference

31 July 2017

Alexandre Carpentier

1

1 reference

31 July 2017

Philippe Metellus

2

1 reference

31 July 2017

Renata Ursu

3

1 reference

31 July 2017

Sarah Zohar

4

1 reference

31 July 2017

Francois Lafitte

5

1 reference

31 July 2017

Maryline Barrié

6

1 reference

31 July 2017

Yuxia Meng

7

1 reference

31 July 2017

Margaretha Richard

8

1 reference

31 July 2017

Dimitri Psimaras

12

1 reference

31 July 2017

Annick Tibi

14

1 reference

31 July 2017

Antoine F Carpentier

16

1 reference

31 July 2017

language of work or name

1 reference

25 January 2010

1 reference

31 July 2017

1 reference

31 July 2017

12

1 reference

31 July 2017

4

1 reference

31 July 2017

401-408

1 reference

describes a project that uses

31 July 2017

Bayes' theorem

1 reference

18 June 2022

https://europepmc.org/article/PMC/2940609

inferred from PubMed Central ID database lookup

cites work

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Incidence of symptomatic hemorrhage after stereotactic electrode placement

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Therapeutic potential of Toll-like receptor 9 activation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

MethyLight: a high-throughput assay to measure DNA methylation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Expression of TLR9 within human glioblastoma.

5 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP047

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP047

Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP047

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNEUONC%2FNOP047

TLR signaling tailors innate immune responses in human microglia and astrocytes

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Incidence of hemorrhage associated with electrophysiological studies performed using macroelectrodes and microelectrodes in functional neurosurgery

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

Response criteria for phase II studies of supratentorial malignant glioma

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2940609

A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20308317

12 December 2020

inferred from PubMed ID database lookup

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20308317

12 December 2020

inferred from PubMed ID database lookup

Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20308317

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1093/NEUONC/NOP047

1 reference

31 July 2017

1 reference

31 July 2017

1 reference